Antiangiogenic activity of aplidine, a new agent of marine origin

British Journal of Cancer

Volumn 90, Issue 12, 2004, Pages 2418-2424

  Taraboletti, G ^a   Poli, M ^a   Dossi, R ^a   Manenti, L ^a   Borsotti, P ^a   Faircloth, G T ^c   Broggini, M ^b   D'Incalci, M ^b   Ribatti, D ^d   Giavazzi, R ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c PharmaMar USA Inc   (United States)

^d UNIVERSITY OF BARI   (Italy)

Author keywords

Angiogenesis inhibition; Aplidine; Didemnin; Endothelial cells

Indexed keywords

DEHYDRODIDEMNIN B; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; MATRIGEL; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CYCLOPEPTIDE; DEPSIPEPTIDE; MATRIX METALLOPROTEINASE;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL FUNCTION; CELL INVASION; CELL LINE; CELL MIGRATION; CELL PROLIFERATION; CHICK EMBRYO; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; FETUS MEMBRANE; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; ANIMAL; BIOASSAY; CAPILLARY; CULTURE TECHNIQUE; CYTOLOGY; NEOVASCULARIZATION (PATHOLOGY); UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; BIOLOGICAL ASSAY; CAPILLARIES; CELL CULTURE TECHNIQUES; CHICK EMBRYO; DEPSIPEPTIDES; ENDOTHELIAL CELLS; HUMANS; MATRIX METALLOPROTEINASES; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDES, CYCLIC; UMBILICAL VEINS;

EID: 3042743711     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601864     Document Type: Article

References (40)

1. Albella B, Faircloth G, Lopez-Lazaro L, Guzman C, Jimeno J, Eueren JA (2002) In vitro toxicity of ET-743 and aplidine, two marine-derived antineoplastics, on human bone marrow haematopoietic progenitors. Comparison with the clinical results. Eur J Cancer 38: 1395-1404
2. Armand JP, Ady-Vago N, Faivre S, Chieze S, Baudin E, Ribrag V, Lecot F, Iglesias L, Lopez-Lazaro L, Guzman C, Jimeno J, Ducreux M, Le Chevalier T, Raymond E (2002) Phase I and pharmacokinetic study of aplidine (APL) given as a 24-hour continuous infusion every other week (q2w)in patients (pts) with solid tumor (ST) and lymphoma (NHL). Proc Am Soc Clin Oncol 20: 120a
3. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G, Giavazzi R, Taraboletti G (1996) The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 2: 1843-1849
4. Broggini M, Marchini SV, Galliera E, Borsotti P, Taraboletti G, Erba E, Sironi M, Jimeno J, Faircloth GT, Giavazzi R, D'Incalci M (2003) Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4. Leukemia 17: 52-59
5. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257
6. Crews CM, Collins JL, Lane WS, Snapper ML, Schreiber SL (1994) GTP-dependent binding of the antiproliferative agent didemnin to elongation factor 1 alpha. J Biol Chem 269: 15411-15414
7. Crews CM, Lane WS, Schreiber SL (1996) Didemnin binds to the protein palmitoyl thioesterase responsible for infantile neuronal ceroid lipofuscinosis. Proc Natl Acad Sci USA 93: 4316-4319
8. D'Amato RJ, Loughnan MS, Flynn E, Folkman J (1994) Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91: 4082-4085
9. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products in anticancer therapy. Curr Opin Pharmacol 1: 364-369
10. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J, Hanauske AR (1998) In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78: 739-744
11. Erba E, Bassano L, Di Liberti G, Muradore I, Chiorino G, Ubezio P, Vignati S, Codegoni A, Desiderio MA, Faircloth G, Jimeno J, D'Incalci M (2002) Cell cycle phase perturbations and apoptosis in tumour cells induced by aplidine. Br J Cancer 86: 1510-1517
12. Erba E, Serafini M, Gaipa G, Tognon G, Marchini S, Celli N, Rotilio D, Broggini M, Jimeno J, Faircloth G, Biondi A, D'Incalci M (2003) Effect of aplidin in acute lymphoblastic leukaemia cells. Br J Cancer 89: 763-773
13. Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31
14. Fusetti L, Pruneri G, Gobbi A, Rabascio C, Carboni N, Peccatori F, Martinelli G, Bertolini F (2000) Human myeloid and lymphoid malignancies in the non-obese diabetic/severe combined immunodeficiency mouse model: frequency of apoptotic cells in solid tumors and efficiency and speed of engraftment correlate with vascular endothelial growth factor production. Cancer Res 60: 2527-2534
15. Gajate C, An F, Mollinedo F (2003) Rapid and selective apoptosis in human leukemic cells induced by aplidine through a Fas/CD95- and mitochondrial- mediated mechanism. Clin Cancer Res 9: 1535-1545
16. Geldof AA, Mastbergen SC, Henrar RE, Faircloth GT (1999) Cytotoxicity and neurocytotoxicity of new marine anticancer agents evaluated using in vitro assays. Cancer Chemother Pharmacol 44: 312-318
17. Gomez SG, Faircloth G, Lopez-Lazaro L, Jimeno J, Bueren JA, Albella B (2001) In vitro hematotoxicity of aplidine on human bone marrow and cord blood progenitor cells. Toxicol In vitro 15: 347-350
18. Gomez-Fabre PM, de Pedro E, Medina MA, Nunez de Castro I, Marquez J (1997) Polyamine contents of human breast cancer cells treated with the cytotoxic agents chlorpheniramine and dehydrodidemnin B. Cancer Lett 113: 141-144
19. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135
20. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105: 1045-1047
21. Jimeno JM (2002) A clinical armamentarium of marine-derived anti-cancer compounds. Anticancer Drugs 13: S15-S19
22. Kerbel R, Folkman J (2002) Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2: 727-739
23. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105: R15-R24
24. Knighton D, Ausprunk D, Tapper D, Folkman J (1977) Avascular and vascular phases of tumour growth in the chick embryo. Br J Cancer 35: 347-356
25. Lobo C, Garcia-Pozo SG, Nunez de Castro I, Alonso FJ (1997) Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res 17: 333-336
26. Marchini S, Chiorino G, Faircloth GT, D'Incalci M (2002) Changes in gene expression profile induced by the anticancer agent Aplidine in Molt-4 leukemic cell lines. J Biol Regul Homeost Agents 16: 241-248
27. Miller KD, Sweeney CJ, Sledge Jr GW (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19: 1195-1206
28. Morigi M, Macconi D, Zoja C, Donadelli R, Buelli S, Zanchi C, Ghilardi M, Remuzzi G (2002) Protein overload-induced NF-kappaB activation in proximal tubular cells requires H(2)O(2) through a PKC-dependent pathway. J Am Soc Nephrol 13: 1179-1189
29. O'Byrne KJ, Dalgleish AG, Browning MJ, Steward WP, Harris AL (2000) The relationship between angiogenesis and the immune response in carcinogenesis and the progression of malignant disease. Eur J Cancer 36: 151-169
30. Raje N, Anderson KC (2002) Thalidomide and immunomodulatory drugs as cancer therapy. Curr Opin Oncol 14: 635-640
31. Ribatti D, Gualandris A, Bastaki M, Vacca A, Iurlaro M, Roncali L, Presta M (1997) New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J Vasc Res 34: 455-463
32. Ribatti D, Nico B, Vacca A, Roncali L, Burri PH, Djonov V (2001) Chorioallantoic membrane capillary bed: a useful target for studying angiogenesis and anti-angiogenesis in vivo. Anat Rec 264: 317-324
33. Sakai R, Rinehart KL, Kishore V, Kundu B, Faircloth G, Gloer JB, Carney JR, Namikoshi M, Sun F, Hughes Jr RG, Garcia Gravalos D, de Quesada TG, Wilson GR, Heid RM (1996) Structure-activity relationships of the didemnins. J Med Chem 39: 2819-2834
34. Schirner M (2000) Antiangiogenic chemotherapeutic agents. Cancer Metast Rev 19: 67-73
35. Schwartsmann G, Brondani da Rocha A, Berlinck RG, Jimeno J (2001) Marine organisms as a source of new anticancer agents. Lancet Oncol 2: 221-225
36. Taraboletti G, Garofalo A, Belotti D, Drudis T, Borsotti P, Scanziani E, Brown PD, Giavazzi R (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J Natl Cancer Inst 87: 293-298
37. Taraboletti G, Micheletti G, Rieppi M, Poli M, Turatto M, Rossi C, Borsotti P, Roccabianca P, Scanziani E, Nicoletti MI, Bombardelli E, Morazzoni P, Riva A, Giavazzi R (2002) Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. Clin Cancer Res 8: 1182-1188
38. Turk BE, Su Z, Liu JO (1998) Synthetic analogues of TNP-470 and ovalicin reveal a common molecular basis for inhibition of angiogenesis and immunosuppression. Bioorg Med Chem 6: 1163-1169
39. Urdiales JL, Morata P, Nunez De Castro I, Sanchez-Jimenez F (1996) Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 102: 31-37
40. Vera MD, Joullie MM (2002) Natural products as probes of cell biology: 20 years of didemnin research. Med Res Rev 22: 102-145